Skip to main content
Equibles
GPCR logo

GPCR · Structure Therapeutics Inc. · Metrics

Track GPCR — free

Use GPCR with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research GPCR.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$40.32 -0.91 (-2.21%)
Rebalance outlook locked
Market Cap
$3.17B
Shares
71.31M

GPCR metrics

49 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$41.23
Market cap
$3.17B

Price action

20 metrics
Price change (1W)
-14.3%
Price change (30D)
-25.0%
Price change (3M)
-2.1%
Price change (6M)
-30.6%
Price change (YTD)
-41.9%
Price change (1Y)
+93.6%
Trailing year
Price change (5Y)
—
52-week high
$93.79
52-week low
$20.20
Change from 52-week high
-56.9%
Change from 52-week low
+99.9%
Annualized volatility
119.4%
Annualized volatility (3M)
57.2%
Beta
1.0
RSI (14D)
26.8
Price vs SMA 50
-20.0%
Price vs SMA 200
-25.8%
Avg volume (3M)
781,620
Relative volume
4.4
Average dollar volume
$37.78M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
71.31M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
2.3
reciprocal yield 42.8%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-6.8%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2024-11-13

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$257.81M
Net income (TTM)
−$214.84M
Trailing 12 months
Diluted EPS (TTM)
$-1.01
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$7.14

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+26.2%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-15.9%
Return on assets
-15.1%
Debt / equity
—
Current ratio
20.8
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
20.8
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$1.34B
Latest balance sheet
Cash & equivalents
$272.64M
Total assets
$1.43B
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$220.29M
Capital expenditures (TTM)
$4.21M
R&D (TTM)
$294.24M
SG&A (TTM)
—
Stock compensation (TTM)
$39.84M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
193
13F filer change QoQ
-6
Institutional ownership
95.5%

Short interest

3 metrics
Short interest
8.5%
Latest settlement · 10.4 days to cover
Days to cover
10.4d
Short-squeeze score
55 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1888886 CUSIP 86366E106 13F (30d) 134 filings 134 filers Visit website Investor relations